XOMA (NASDAQ:XOMA) Downgraded to “Sell” Rating by StockNews.com

StockNews.com cut shares of XOMA (NASDAQ:XOMA) from a hold rating to a sell rating in a report published on Monday.

Separately, HC Wainwright lowered their price target on shares of XOMA from $123.00 to $104.00 and set a “buy” rating for the company in a research report on Monday.

XOMA Stock Down 6.5 %

Shares of NASDAQ:XOMA opened at $24.88 on Monday. The stock has a market capitalization of $293.09 million, a price-to-earnings ratio of -7.15 and a beta of 0.90. XOMA has a 1-year low of $19.50 and a 1-year high of $35.00. The company’s fifty day moving average is $27.72 and its two-hundred day moving average is $28.07. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

XOMA (NASDAQ:XOMA) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05. The company had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $6.66 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. Equities analysts anticipate that XOMA will post -1.41 EPS for the current year.

Insider Activity at XOMA

In other XOMA news, CEO Owen Hughes sold 21,881 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the sale, the chief executive officer now directly owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. This represents a 38.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The disclosure for this sale can be found here. 7.20% of the stock is currently owned by insiders.

Institutional Trading of XOMA

A number of hedge funds have recently bought and sold shares of XOMA. BNP Paribas Financial Markets lifted its stake in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares in the last quarter. New York State Common Retirement Fund lifted its stake in XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 800 shares in the last quarter. Rhumbline Advisers lifted its stake in XOMA by 18.1% during the fourth quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock valued at $291,000 after buying an additional 1,699 shares in the last quarter. Barclays PLC lifted its stake in XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 8,447 shares in the last quarter. Finally, Ellsworth Advisors LLC purchased a new stake in XOMA during the third quarter valued at about $516,000. 95.92% of the stock is owned by hedge funds and other institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.